Source link : https://www.newshealth.biz/health-news/fda-approves-bizengri-for-nsclc-pancreatic-cancer/
The US Food and Drug Administration (FDA) has granted accelerated approval to zenocutuzumab-zbco (Bizengri, Merus) as an intravenous infusion for the treatment of certain adults with non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma. Specifically, the systemic agent was approved for those with advanced, unresectable, or metastatic NSCLC or pancreatic adenocarcinoma harboring a neuregulin 1 […]
Author : News Health
Publish date : 2024-12-04 23:11:55
Copyright for syndicated content belongs to the linked Source.